Animal welfare and the refinement of neuroscience research methods - A case study of Huntington's disease models

Laboratory Animals

Volumn 42, Issue 3, 2008, Pages 277-283

  Olsson, I Anna S ^a,b   Hansen, Axel K ^b   Sandøe, Peter ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Animal models; Animal welfare; Huntington's disease; Neuroscience research methods

Indexed keywords

3 NITROPROPIONIC ACID; NEUROTOXIN; QUINOLINIC ACID;

ANIMAL WELFARE; ARTICLE; DEGENERATIVE DISEASE; DEHYDRATION; DISEASE SEVERITY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; HUNTINGTON CHOREA; LETHALITY; MALNUTRITION; MEDICAL ETHICS; MEDICAL LITERATURE; MEDICAL RESEARCH; MORTALITY; NEUROSCIENCE; NONHUMAN; SENSORIMOTOR FUNCTION;

ANIMAL WELFARE; ANIMALS; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; MICE; PUBLICATIONS; QUESTIONNAIRES; RATS;

ANIMALIA;

EID: 47749100817     PISSN: 00236772     EISSN: None     Source Type: Journal    
DOI: 10.1258/la.2008.007147     Document Type: Article

References (36)

1. Animal Procedures Committee (2003) Review of Cost-benefit Assessment in the Use of Animals in Research. London: Home Office
2. Anonymous (2007) See http:// www.alzet.com/products/pump_selection. php#animalsize (last checked 10 May 2007)
3. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-71
4. Blum D, Galas MC, Pintor A, et al. (2003) Dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. Journal of Neuroscience 23, 5361-9
5. Brouillet E, Condé F, Beal MF, Hantraye P (1999) Replicating Huntington's disease phenotype in experimental animals. Progress in Neurobiology (Oxford) 59, 427-66
6. Brouillet E, Jenkins B, Hyman B, et al. (1993) Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. Journal of Neurochemistry 60, 356-9
7. Canadian Council on Animal Care (1991) Categories of Invasiveness in Animal Experiments. See http:// www.ccac.ca/en/CCAC_Programs/ Guidelines_Policies/POLICIES/CATEG.HTM (last checked 10 May 2007)
8. Dedeoglu A, Kubilus JK, Yang L, et al. (2003) Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of Neurochemistry 85, 1359-67
9. Demers G, Griffin G, De Vroey G, et al. (2006) Harmonization of animal care and use guidance. Science 312, 700-1
10. Diguet E, Fernagut PO, Normand E, Centelles L, Mulle C, Tisona F (2004) Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history. Neurobiology of Disease 15, 667-75
11. Fernagut PO, Diguet E, Stefanova N, et al. (2002) Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57BL/6 mice: behavioural and histopathological characterization. Neuroscience 114, 1005-17
12. Ferrante RJ, Ryu H, Kubilus JK, et al. (2004) Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. Journal of Neuroscience 24, 10335-42
13. Hockly E, Woodman B, Mahal A, Lewis CM, Bates G (2003) Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Research Bulletin 61, 469-79
14. Hockly E, Richon VM, Woodman B, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America 100, 2041-6
15. Home Office (2000) Guidance on the Operation of the Animals (Scientific Procedures) Act 1986. See http:// www.archive.official- documents.co.uk/ document/hoc/321/321-05.htm#gen114 (last checked 10 May 2007)
16. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF (2003) Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry 86, 267-72
17. Li JY, Popovic N, Brundin P (2005) The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2, 447-64
18. Mangiarini L, Sathasivam K, Seller M, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506
19. Morton DB, Hau J (2002) Welfare assessment and humane endpoints. In: Handbook of Laboratory Animal Science. 2nd edn. (Van Hoosier G, Hau J, eds). Boca Raton: CRC Press, 457-86
20. Naver B, Stub C, Møller M, et al. (2003) Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 122, 1049-57
21. Norflus F, Nanje A, Gutekunst CA, et al. (2004) Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiology of Disease 17, 319-25
22. Nuffield Council on Bioethics (2005) The Ethics of Research Involving Animals. London: Nuffield Council on Bioethics
23. OECD (2000) OECD Test Guideline 401 will be deleted: A Major Step in Animal Welfare: OECD Reaches Agreement on the Abolishment of the LD50 Acute Toxicity Test. See http:// www.oecd. org/document/52/0,2340, en_2649_34377_2752116_ 1_1_1_1,00.html (last checked 10 May 2007)
24. Olsson IAS, Hansen AK, Sandøe P (2007) Ethics and refinement in animal research. Science 317, 1680
25. Olsson IAS, Robinson P, Pritchett K, Sandøe P (2002) Animal research ethics. In: Handbook of Laboratory Animal Science. 2nd edn. (Van Hoosier G, Hau J, eds). Boca Raton: CRC Press, 13-30
26. Paul EF, Paul J eds (2000) Why Animal Experimentation Matters: The Use of Animals in Medical Research. New Brunswick: Transaction Publishers
27. Ribchester RR, Thomson D, Wood NI, et al. (2004) Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. European Journal of Neuroscience 20, 3092-114
28. Richardson CA, Flecknell PA (2005) Anaesthesia and post-operative analgesia following experimental surgery in laboratory rodents: are we making progress? ATLA Alternatives to Laboratory Animals 33, 119-27
29. Russell WMS, Burch RL (1959/1992) The Principles of Humane Experimental Technique. See http:// altweb.jhsph.edu/publications/ humane_exp/ foreword.htm
30. Saydoff JA, Liu LS, Garcia RAG, Hua Z, Lib D, von Borstel RW (2003) Oral uridine pro-drug PN401 decreases neurodegeneration, behavioural impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease. Brain Research 994, 44-54
31. Schiefer J, Sprü nken A, Puls C, et al. (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Research 1019, 246-54
32. Schilling G, Becher MW, Sharp AH, et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Human Molecular Genetics 8, 397-407
33. Smaje LH, Smith JA, Ewbank R, et al. (1998) Advancing refinement of laboratory animal use. Laboratory Animals 32, 137-42
34. Stokes WS (2000) Reducing unrelieved pain and distress in laboratory animals using humane endpoints. ILAR Journal 41. See http:// dels.nas. edu/ilar_n/ilarjournal/41_2/41_2Introduction. shtml (last checked 10 May 2007)
35. Walker FO (2007) Huntington's disease. Lancet 369, 218-28
36. Würbel H (2007) Publications should include an animal-welfare section. Nature 446, 257